Pediatric Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Pediatric Drugs and Medicines Market is segmented by Drug Type (Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs, and Other Drug Types), Route of Administration (Oral, Topical, Parenteral, and Other Routes of Administration), and Geography (North America, Europe, Asia-Pacific, Middle-East, and Africa, and South America). The report offers the value (in USD million) for the above segments.

Pediatric Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Pediatric Drugs Industry Overview

The pediatric drugs market is moderately competitive and consists of several major players. A few major players are currently dominating the market in terms of market share. Some prominent players are launching new products to address the unmet challenges in the market, while others are distributing the products. For instance, in April 2019, GSK received approval from the US Food and Drug Administration (FDA) for its intravenous (IV) Benlysta (belimumab), the first medicine approved in the US for children with systemic lupus erythematosus (SLE) from as young as five years of age cranial defects. Some companies currently dominating the market include BioMarin Pharmaceutical Inc., Horizon Therapeutics PLC, Sumitomo Dainippon Pharma Co. Ltd, Gilead Sciences Inc., and Jazz Pharmaceuticals Inc.

Pediatric Drugs Market Leaders

  1. BioMarin Pharmaceutical Inc

  2. Horizon Therapeutics plc

  3. Sumitomo Dainippon Pharma Co Ltd

  4. Jazz Pharmaceuticals Inc

  5. Gilead Sciences Inc

  6. *Disclaimer: Major Players sorted in no particular order
BioMarin Pharmaceutical Inc., Horizon Therapeutics PLC, Sumitomo Dainippon Pharma Co. Ltd, Gilead Sciences Inc., and Jazz Pharmaceuticals Inc.